Results
|
|
81.
|
|
|
|
82.
|
|
|
|
83.
|
|
|
|
84.
|
|
|
|
85.
|
|
|
|
86.
|
|
|
|
87.
|
|
|
|
88.
|
|
|
|
89.
|
|
|
|
90.
|
|
|
|
91.
|
|
|
|
92.
|
|
|
|
93.
|
|
|
|
94.
|
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. [electronic resource] by
- Macrae, Fraser L
- Peacock-Young, Barnaby
- Bowman, Polly
- Baker, Stephen R
- Quested, Sam
- Linton, Emma
- Hillmen, Peter
- Griffin, Morag
- Munir, Talha
- Payne, Daniel
- McKinley, Claire
- Clarke, Deborah
- Newton, Darren J
- Hill, Anita
- Ariëns, Robert A S
Producer: 20200917
In:
American journal of hematology vol. 95
Availability: No items available.
|
|
|
95.
|
|
|
|
96.
|
|
|
|
97.
|
|
|
|
98.
|
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. [electronic resource] by
- Rondeau, Eric
- Scully, Marie
- Ariceta, Gema
- Barbour, Tom
- Cataland, Spero
- Heyne, Nils
- Miyakawa, Yoshitaka
- Ortiz, Stephan
- Swenson, Eugene
- Vallee, Marc
- Yoon, Sung-Soo
- Kavanagh, David
- Haller, Hermann
Producer: 20210621
In:
Kidney international vol. 97
Availability: No items available.
|
|
|
99.
|
|
|
|
100.
|
|